This study sought to demonstrate the noninferiority of endothelial progenitor cell capturing stents (ECS) relative to drug-eluting stents (DES) regarding target lesion failure (TLF) and the composite of cardiac death, myocardial infarction, and target lesion repeat revascularization within 1 year.
Drug-eluting stents (DES) reduce in-stent restenosis and repeat revascularization compared with bare-metal stents for the treatment of coronary artery disease (1) (2) (3) (4) . The polymer-regulated delivery of cytotoxic or cytostatic drugs at the site of stent placement inhibits the proliferation of vascular smooth muscle cells (SMC) that gives rise to neointimal hyperplasia that causes in-stent restenosis (1) (2) (3) 5, 6) . By their nature, antiproliferative drugs not only inhibit SMC growth, reducing the occurrence of angiographic restenosis and subsequent need for repeat target lesion revascularization (TLR), but also impede the formation of a normal, functional endothelial lining covering the damaged vessel wall and stent (7, 8) . Disturbing the natural healing response of the vessel wall may lead to an increased incidence of stent thrombosis (ST), which necessitates prolonged dual antiplatelet therapy (9, 10) .
Circulating endothelial progenitor cells (EPCs) have regenerative capacities and play an important role in vessel wall homeostasis (11, 12) . When attracted to the site of vessel wall injury, EPCs rapidly differentiate into a functional layer as part of the healing process. Accelerated re-endothelialization after stent placement may reduce in-stent restenosis by reducing neointimal hyperplasia and SMC proliferation and, additionally, the occurrence of ST (13) . The endothelial progenitor cell capturing stent (ECS) is coated with a polysaccharide matrix and covalently coupled monoclonal murine anti-human CD34 ϩ antibodies. These anti-CD34 ϩ antibodies are able to bind bone marrow-derived circulating EPCs from the peripheral blood, and in animal models, it was shown that these EPCs rapidly differentiate into a functional endothelial layer after immobilization (14 -16) .
In humans, the ECS was first evaluated in several small studies. The nonrandomized Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First in Man (HEALING-FIM) and the HEALING II studies enrolled patients with noncomplex coronary lesions, and Co et al. and Lee et al. enrolled ST-segment elevation myocardial infarction (MI) patients (13, (17) (18) (19) (20) . These studies showed low repeat revascularization rates and an absence of ST. The novel technology of enhancing the body's own healing response and the promising results of the HEALING studies led to our confidence that the ECS would be equivalent to DES in terms of preventing restenosis in complex patients and lesions. The TRIAS HR (TRI-stent Adjudication Study-High Risk of restenosis) trial aimed to demonstrate noninferiority of the ECS when compared with DES to prevent target lesion failure (TLF) within 1 year in patients with lesions carrying a high risk of restenosis.
Methods
Patient population and protocol. The design of the TRIAS HR trial has been described previously (21) . In brief, the TRIAS HR trial was an investigator-initiated, prospective, multicenter, single-blind, randomized clinical trial enrolling patients between April 2007 and February 2009 in 26 sites worldwide (Online Appendix). Patients selected for elective percutaneous coronary intervention (PCI) were candidates for enrollment in the TRIAS HR trial when at least 1 target lesion had been identified as carrying a high risk of restenosis. A lesion was defined as a high-risk lesion when 1 or more of the following criteria were met: 1) a lesion in a coronary artery with a reference vessel diameter of Յ2.8 mm by visual estimation; 2) a coronary artery stenosis with a length of Ն20 mm by visual estimation; 3) a chronic coronary artery occlusion; or 4) any lesion in a diabetic patient. Major exclusion criteria included left main coronary artery disease, bifurcation lesions with a side branch that was Ն2.0 mm in diameter by visual estimation, restenotic lesions, grafts or lesions distal to a diseased graft, the occurrence of an MI within the past 6 weeks, known renal insufficiency or suspected liver disease, known hypersensitivity or contraindication to aspirin, heparin, or clopidogrel, and elective surgery planned within the first 6 months after the procedure that required discontinuation of either aspirin or clopidogrel. Eligible patients signed written, informed consent prior to the index PCI procedure.
Patients were randomly assigned to either of the following treatment strategies: 1) treatment with an ECS (Genous Bio-engineered R stent, OrbusNeich Medical Technologies, Fort Lauderdale, Florida); or 2) treatment with a DES. The following DES were allowed to be used in the TRIAS HR trial: any Taxus paclitaxel-eluting stent (PES) (Boston Scientific, Natick, Massachusetts), the Cypher sirolimus-eluting stent (SES) (Cordis Corporation, Miami, Florida), the XIENCE V everolimus-eluting stent (EES) (Abbott Vascular, Abbott Park, Illinois), and the Endeavor zotarolimus-eluting stent (ZES) (Medtronic, Minneapolis, Minnesota). The choice of any of these 4 DES was at the discretion of the operator. However, in case of multiple lesions per patient, it was recommended to use the same type of DES in all treated lesions when the patient was assigned to receive DES. Patients were randomized at the time of the PCI procedure as soon as their coronary anatomy was known and suitable for enrollment, and when all inclusion criteria were met. Prior to the randomization, the operator identified all target lesions and nontarget lesions that were planned to be treated. The treatment modality of the nontarget lesions was left to the discretion of the operator. Randomization was performed via an electronic case report form (eCRF) program accessible by entering the randomization website (www.triasrandomization.org). Randomization blocks were created with randomly chosen block sizes.
Before and after the index procedure, it was advised that all patients receive aspirin 75 to 100 mg daily, and a loading dose of 300 mg of clopidogrel prior to the procedure. Thereafter, 75 mg of clopidogrel was prescribed daily for at least 1 month according to the Instructions for Use after receiving an ECS and at least 6 months according to the ACC/AHA/SCAI PCI practice guidelines after receiving a DES (22) .
Clinical follow-up was obtained at 1, 6, and 12 months and will be collected yearly through 5 years either by telephone contact or a planned visit to the clinic. All data entered in the electronic eCRF were verified for completeness. On-site study monitors verified all source data when major adverse events, as defined in the study protocol, were reported in the eCRF. Furthermore, all entered eCRF data from Ͼ20% of the event-free patients were verified with the patient's source data. The study complied with the principles of the Declaration of Helsinki regarding investigation in humans and was approved by the local institutional review board at each participating center. Endpoints and data management. The pre-specified primary endpoint was TLF, defined as the composite of cardiac death, MI (unless documented to unequivocally arise from a nontreated coronary artery), and clinically driven TLR of any of the target lesions at 12 months. All deaths were considered cardiac unless an unequivocal noncardiac cause could be established. Definitions for the endpoints and the methodology for their ascertainment have been reported previously and were in accordance with the Academic Research Consortium recommendations (21, 23) .
All reported deaths, potential MI, revascularization procedures, and ST were adjudicated by an independent clinical event committee whose members were blinded to the randomized treatment allocation after review of original source documentation. Angiographic follow-up. In a subset of patients enrolled in the TRIAS HR trial, repeat angiography will be performed between 13 and 15 months. All principal investigators of the participating centers have been invited to participate in this angiographic substudy. Two investigators agreed and all consecutive patients in these centers have been asked to participate. These data will be addressed in a separate analysis.
Statistical analysis. This trial was designed as a noninferiority study, which was powered for noninferiority on the primary clinical endpoint at 12 months. On the basis of the event rates that were reported in the TAXUS IV trial (24, 25) , the HEALING II trial (13, 19) , and the results of the e-HEALING registry (26), we expected equal TLF rates of 10%, with a margin of noninferiority of 1.5 for the relative risk. With 2 ϫ 620 analyzable patients, the trial had 90% power to detect noninferiority of the ECS with a 1-sided alpha of 5%. To compensate for an attrition of 5%, we aimed to enroll 2 ϫ 650 patients into the trial. However, early cessation of enrollment was recommended by the data and safety monitoring board (DSMB) during a routine review to assess the safety of the trial. This review occurred when the first 50% of the patients planned to be enrolled were included, with a mean follow-up of 8.5 months. The DSMB noted that ECS-treated patients exhibited a higher TLR rate compared with the control arm. Importantly, the DSMB reached the conclusion that the pre-specified noninferiority endpoint could no longer be met and that enrollment of new patients in the study would be unreasonable, and therefore, the trial should be terminated for safety reasons. Directly thereafter, enrollment was discontinued on February 19, 2009. Cumulative event rates at 12 months were estimated with the Kaplan-Meier method. In these analyses, patients who were lost to follow-up were censored at the time of last contact. Relative risks were calculated by dividing the estimated event rate at 12 months in the ECS-treated arm by that in the DES arm. For the primary endpoint, the 1-sided p value for noninferiority was calculated by comparing the relative risk to the a priori hypothesized margin of noninferiority. For all other endpoints, no formal hypothesis testing was performed. Henceforth, for all other endpoints, the 95% confidence intervals (CI) are presented for descriptive purposes only.
We included all randomized patients that received treatment in pre-specified high-risk lesions in the analysis of primary and secondary clinical outcomes according to the randomized treatment assignment; irrespective of the treatment they actually received (intention-to-treat principle). Endpoint assessments were based on a per-patient analysis. In patients with multiple high-risk lesions treated, TLR had occurred if TLR had been performed on at least 1 or more of the treated high-risk study lesions. Lesions pre-specified as carrying a low risk of restenosis and treated during the baseline procedure were analyzed as nontarget lesions irrespective of the treatment they received. The statistical analysis was performed with the Statistical Package for Social Sciences (SPSS) software version (version 16, SPSS, Chicago, Illinois) and with R, version 2.9.2 (R Foundation for Statistical Computing, Vienna, Austria). This study is registered with the ISRCTN Register (ISRCTN74297220). N S , V O L . 4 , N O . 8 , 2 0 1 1 A U G U S T 2 0 1 1 : 8 9 6 -9 0 4 Klomp et al.
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Results
In total, 658 patients were randomized in the eCRF (Fig. 1) . Thirty-six patients were excluded for technical reasons or lack of data. (In short, in 20 patients, no attempt was made to implant a study stent, 2 patients met exclusion criteria after premature randomization, and 1 site failed to provide baseline data or any follow-up data beyond that despite repeated requests to do so. We excluded all 14 patients from this site from the analysis). A total of 622 patients were randomly assigned to receive either an ECS (304 patients, 367 lesions) or DES (318 patients, 388 lesions). A total of 294 (96.7%) patients randomized to ECS and 314 (98.7%) patients randomized to DES received at least 1 allocated study stent. Six (2.0%) patients randomized to ECS and 3 (0.9%) patients randomized to DES were lost to follow-up or withdrew consent within 12 months. Furthermore, a total of 32 pre-specified low-risk lesions were treated in patients randomized to receive an ECS and 24 low-risk lesions in patients randomized to receive DES.
Baseline clinical and angiographic characteristics were comparable between both populations. Over 70% of the patients were male, and almost 50% had diabetes mellitus (Table 1) . Furthermore, 70% of the treated lesions were type B2/C lesions, the average lesion length was 22 mm, and mean vessel diameter was 3 mm (Table 2) . Of the patients assigned to receive DES treatment, 61% received a PES, 16% received a ZES, 14% a SES, 5% an EES, and 4% received a combination of different stent types, a bare-metal stent, or a nonstudy DES. Single-lesion intervention occurred in 251 (82.6%) patients that were treated with the ECS and in 259 (81.4%) patients treated with DES. Procedural success was similar for the 2 populations. Values are mean Ϯ SD or n (%). No statistically significant differences were found between both groups.
CABG ϭ coronary artery bypass grafting; DES ϭ drug-eluting stent(s); MI ϭ myocardial infarction; PCI ϭ percutaneous coronary intervention; STEMI ϭ ST-segment elevation myocardial infarction.
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The clinical outcomes are summarized in Table 3 . The primary endpoint of TLF defined as the composite of cardiac death, target lesion-related MI, and clinically driven TLR, occurred in 17.4% (95% CI: 13.0 to 21.6) of the patients treated with ECS and in 7.0% (95% CI: 4.1 to 9.8) of the patients treated with DES. We could not establish noninferiority of the ECS compared with DES (relative risk: 2.5; 95% CI: 1.6 to 4.0; p ϭ 0.98 for noninferiority).
The cumulative event rate of TLF for both treatment arms is shown in Figure 2 . The findings for the primary endpoint in patients with diabetes mellitus showed an occurrence of TLF of 19.8% in diabetic patients (n ϭ 140) treated with ECS versus 8.7% in diabetic patients treated with DES (n ϭ 151).
Clinically indicated TLR at 1 year was more common in patients randomly assigned to the ECS than to the DES (15.2% versus 5.7%, relative risk: 2.6; 95% CI: 1.6 to 4.5). These findings demonstrate that TLF was mainly driven by TLR. Figure 3 shows TLR over time.
We recorded a total of 2% of the patients allocated to receive the ECS that died of cardiac causes versus 1% allocated to receive DES, and 4% versus 1% of the patients had a target lesion-related MI.
Target vessel failure (TVF)-a composite of cardiac death, target vessel-related MI and target vessel revascular- Values are n, mean Ϯ SD, or n (%). No statistically significant differences were found between both groups.
ACC/AHA ϭ American College of Cardiology/American Heart Associ8ation; DES ϭ drug-eluting stent(s); TIMI ϭ Thrombolysis In Myocardial Infarction. Values are n (%). *Target lesion failure is defined as the composite of cardiac death, MI attributable to the target lesion, or clinically driven target lesion revascularization (TLR).
TVF ϭ target vessel failure; TVR ϭ target vessel revascularization; other abbreviations as in Table 1 .
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ization (TVR)-occurred in 17.4% of the patients allocated to the ECS and in 8.6% of the patients allocated to DES. Stent thrombosis occurred in 8 patients after ECS implantation, of which 6 were definite ST at 5, 6, 38, 81, 84, and 313 days, respectively, and in 3 patients after DES implantation, of which 1 was definite ST only hours after DES implantation (Table 4) . At the time of the ST event, 1 patient in the ECS arm had discontinued dual antiplatelet therapy 10 days before the ST due to a hip surgery. All other patients were on dual antiplatelet therapy at the time of the event. Furthermore, 1 definite ST occurred in an ECStreated patient who received an EES 125 days after the baseline procedure for the treatment of in-stent restenosis. Definite ST occurred on day 313 after ECS implantation and, thus, 188 days after EES implantation.
What is noteworthy, as a result of the recommendation on the duration of dual antiplatelet therapy in the trial, is that the percentage of patients on dual antiplatelet therapy over time was lower in patients that received an ECS when compared with patients that received a DES (Fig. 4) .
Discussion
This is the first large, multicenter, international, randomized clinical trial to compare clinical outcomes of ECS with DES. Our findings indicate that treating patients/lesions with a high risk of restenosis with an ECS results in a worse outcome regarding the primary endpoint of TLF compared with treatment with DES. The incidence of the primary endpoint was 17.4% in patients treated with ECS and 7.0% in patients treated with DES. This difference in TLF was mainly driven by the difference in TLR in ECS-treated patients (15.2% vs. 5.7%) compared with the DES-treated patients. In summary, in terms of restenosis prevention in high-risk patients and lesions within 12 months after stent placement, inhibition of intimal hyperplasia after stent placement with ECS is not sufficiently strong to compete with DES.
Thus far, there are 2 concurrent studies evaluating ECStreated patients with a high risk of restenosis. In the single-center registry by Miglionico et al. (27) , 80 patients with complex lesions were treated with an ECS. A control arm was lacking in the design of this study. At 14-month follow-up, the composite of cardiac death, MI, and TVR was 16%, and the TLR rate was 13%. No cases of ST were reported. In the second study, the single-center, randomized TRIAS pilot study, the ECS was compared with the PES in 193 patients with lesions carrying a high risk of restenosis (28) . The latter study was carried out to investigate the feasibility of the larger, multicenter TRIAS HR trial. At 12-month follow-up, the primary endpoint of TVFdefined as the composite of cardiac death, MI, and TVRoccurred in 17.3% of the ECS-treated patients and in 10.5% of the PES-treated patients (risk difference: 6.8%, 95% CI: Ϫ3.1% to 16.7%). TLR rates were 15.2% and 5.7%, respectively. No cases of ST were observed in patients treated with an ECS versus 4 in patients treated with a PES. : 304  296  283  268  260  253  247  DES: 318  313  309  306  299  296  293 Numbers at risk Numbers at risk The higher TVF rate in patients allocated to receive an ECS in this pilot study was predominantly driven by a higher incidence of TLR. The TVF rate in PES-treated patients was mainly driven by the occurrence of ST. These concurrent smaller studies using ECS show TLR rates comparable to our present analysis, though due to the small number of patients or lack of control arm, one should be careful interpreting their results. Then, several studies have been carried out to evaluate DES in complex lesions with a higher risk of restenosis. The TLR rates in the TAXUS V trial, TAXUS ATLAS study, and LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) trial compare fairly with the 7.0% TLF rate in the patients treated with DES of our trial (24,29 -31) . In conclusion, clinical observations in the TRIAS HR trial evaluating ECS and DES were in line with these earlier observations. The TLF rate in ECS-treated patients in the TRIAS HR trial was mainly driven by TLR. Although DES release cytotoxic or cytostatic drugs to suppress in-stent restenosis, this concurrently impedes re-endothelialization of the stented area, with the subsequent risk of (late) ST (32) . Furthermore, after DES implantation, accumulation of intimal tissue within the stent may continue well beyond the first 9 to 12 months after stent placement (33) . In contrast, the ECS attracts circulating EPCs to promote rapid endothelialization after stent implantation to prevent restenosis. In animal models, the surface of the ECS was covered with an endothelial layer only 48 h after implantation (14 -16) . However, CD34 is a membrane surface marker for bone marrow-derived stem cells, including endothelial and smooth muscle progenitor cells. In humans, the mechanism of potential competition between CD34 ϩ cell differentiation into endothelium or SMC after stent implantation is not well understood. Recently, it was shown that circulating CD34 ECS:  304  225  211  201  180  178  130  DES:  318  311  305  298  266  261  192 Numbers at risk DAPT ϭ dual antiplatelet therapy; ECS ϭ endothelial progenitor cell capturing stent(s); EES ϭ everolimus-eluting stent(s); LAD ϭ left anterior descending coronary artery; RCA ϭ right coronary artery; RCX ϭ ramus circumflexus coronary artery; ST ϭ stent thrombosis; other abbreviations as in Table 1 .
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as a predestined endothelial progenitor cell population but are mostly generated from circulating multipotent CD34 ϩ cells at sites of vascular injury (34) . Furthermore, there is no evidence indicating the potential dependence of the presence of circulating EPCs in both animals and humans to establish complete coverage of the stented area. Nevertheless, longer-term clinical outcome demonstrated an interesting biological phenomenon after ECS implantation. In 2 studies, repeat angiography and intravascular ultrasound at 6 and 18 months after ECS implantation showed a significant late luminal loss reduction between the 2 angiograms (13, 35) . Therefore, for a full comparison of the clinical effectiveness between the ECS and DES, both the late remodeling of intimal hyperplasia tissue and the occurrence of late and very late ST requires long-term follow-up; in the TRIAS HR trial, clinical follow-up will be performed up to 5 years after the initial stent implantation. Yet, the results of the current trial, with patients and lesions with a high risk of restenosis, show that within 12 months, enhanced endothelialization by attracting circulating CD34 ϩ cells is apparently less efficient than DES to prevent SMC proliferation and thereby the occurrence of in-stent-restenosis. Study limitations. The TRIAS HR trial was terminated early and was therefore not powered to evaluate ischemic endpoints or stent thrombosis. In addition, as TRIAS HR was an investigator-initiated study with relatively limited resources and a multicenter, international design, we encountered different DES availability and ongoing stent innovations during the trial. In the current analysis, 4 different types of DES were used due to differences in standard clinical practice among the participating PCI centers. As the superiority of second-generation DES only became evident after the enrollment of the TRIAS HR trial was completed, the majority of the study stents were first-generation DES.
Conclusions
In the TRIAS HR trial, we could not establish noninferiority when comparing the ECS with DES in patients carrying lesions with a high risk of restenosis at 12 months. Furthermore, long-term follow-up is pivotal to fully appreciate the clinical value of ECS, including the effect on late intimal hyperplasia regression.
